Replies to post #225625 on Biotech Values

[rfj1862]

Somebody really messed up at Healio by breaking the embargo.

Key points:

More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell therapy, according to the results of an ongoing phase 1 clinical trial presented at the ACCR’s Immune Cell Therapies for Cancer conference in San Francisco.

The study included three treatment arms in which researchers evaluated the safety and feasibility of multiTAA T cells as well as progression-free and overall survival. Arm A included patients with unresectable or metastatic pancreatic adenocarcinoma whose disease responded to standard first-line chemotherapy. Arm B comprised patients with progressive or refractory disease after first-line chemotherapy. Finally, Arm C included patients with potentially resectable disease.

Treatment Arm A included one patient with a complete response, two with disease progression, five with stable disease or ongoing response (range, 6-9 months) to therapy, and two who are too early to evaluate.
Arm B included patients with progressive disease. The study showed that three patients continued disease progression, while three other patients showed ongoing stable disease (range, 1-6 months).
Arm C included patients with potentially resectable disease; these patients received one preoperative infusion of T cells and are still receiving postoperative infusions and adjuvant therapy.